981-P: Postprandial Hyperglycemia following Insulin Suspensions by the Artificial Pancreas: Implications for Bolus Calculators

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 981-P
Author(s):  
SANDRINE MAJOR ◽  
ANAS EL FATHI ◽  
EMILIE PALISAITIS ◽  
ROBERT E. KEARNEY ◽  
JULIA E. VON OETTINGEN ◽  
...  
Keyword(s):  
Artificial Pancreas ◽  
Postprandial Hyperglycemia

117-LB: DIWHY: Factors Influencing Motivation, Barriers, and Duration of DIY Artificial Pancreas System Use among Real-World Users

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 117-LB ◽  
Author(s):  
KATARINA BRAUNE ◽  
SHANE O’DONNELL ◽  
BRYAN CLEAL ◽  
DANA M. LEWIS ◽  
ADRIAN TAPPE ◽  
...  
Keyword(s):  
Real World ◽  
Artificial Pancreas ◽  
Factors Influencing ◽  
System Use

Effect of an Add-On SGLT2 Inhibitor on the Efficacy of DPP-4 Inhibitor Therapy in Improving Postprandial Hyperglycemia

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 2308-PUB
Author(s):  
TETSUROU ONISHI ◽  
YUKIKO TANIGUCHI ◽  
YUTAKA MORI
Keyword(s):  
Sglt2 Inhibitor ◽  
Postprandial Hyperglycemia ◽  
Inhibitor Therapy

1298-P: “I Would Rather Bolus”: Youth and Parents Prefer Manual Bolusing to Carbohydrate Limitations in a Fully Automated Artificial Pancreas (AP) System

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1298-P
Author(s):  
PERSIS V. COMMISSARIAT ◽  
LINDSAY ROETHKE ◽  
JENNIFER L. FINNEGAN ◽  
LISA K. VOLKENING ◽  
DAYNA E. MCGILL ◽  
...  
Keyword(s):  
Artificial Pancreas

Recent Developments in Alpha-Glucosidase Inhibitors for Management of Type-2 Diabetes: An Update

2019 ◽  
Vol 25 (23) ◽  
pp. 2510-2525 ◽  
Author(s):  
Bashir Usman ◽  
Neha Sharma ◽  
Saurabh Satija ◽  
Meenu Mehta ◽  
Manish Vyas ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Patient Compliance ◽  
Postprandial Hyperglycemia ◽  
Diabetic Patients ◽  
Poor Patient ◽  
Glucosidase Inhibitors ◽  
Poor Patient Compliance ◽  
Recent Developments ◽  
Alpha Glucosidase

The incidence of diabetes has increased globally in recent years and figures of diabetic patients were estimated to rise up to 642 million by 2040. The disorder is accompanied with various complications if not managed at the early stages, and interlinked high mortality rate and morbidity with time. Different classes of drugs are available for the management of type 2 diabetes but were having certain limitations of their safety. Alphaglucosidase is a family of enzyme originated from the pancreas which plays a role in the anabolism of 80-90% of carbohydrate consumed into glucose. This glucose is absorbed into the blood and results in frank postprandial hyperglycemia and worsens the conditions of diabetic patients which precipitate complications. Inhibition of these enzymes helps to prevent postprandial hyperglycemia and the formation of glycated end products. Alphaglucosidase inhibitors are reported to be more important in adequate control of type 2, but marketed drugs have various side effects, such as poor patient compliance and also expensive. This proves the needs for other class of drugs with better efficacy, safety, patient compliance and economic. In this review, we have emphasized the recent advances in the field of new alpha-glucosidase inhibitors with improved safety and pharmacological profile.

The Artificial Pancreas in Cyborg Bodies

2020 ◽  
pp. 412-430
Author(s):  
Anthony Ryan Hatch ◽  
Julia T. Gordon ◽  
Sonya R. Sternlieb
Keyword(s):  
Glucose Sensor ◽  
Social Inequalities ◽  
Infusion Pump ◽  
Artificial Pancreas ◽  
Small Scale ◽  
Glucose Levels ◽  
Loop Design ◽  
Access To Health ◽  
Do It Yourself ◽  
And Control

The new artificial pancreas system includes a body-attached blood glucose sensor that tracks glucose levels, a worn insulin infusion pump that communicates with the sensor, and features new software that integrates the two systems. The artificial pancreas is purportedly revolutionary because of its closed-loop design, which means that the machine can give insulin without direct patient intervention. It can read a blood sugar and administer insulin based on an algorithm. But, the hardware for the corporate artificial pancreas is expensive and its software code is closed-access. Yet, well-educated, tech-savvy diabetics have been fashioning their own fully automated do-it-yourself (DIY) artificial pancreases for years, relying on small-scale manufacturing, open-source software, and inventive repurposing of corporate hardware. In this chapter, we trace the corporate and DIY artificial pancreases as they grapple with issues of design and accessibility in a content where not everyone can become a diabetic cyborg. The corporate artificial pancreas offers the cyborg low levels of agency and no ownership and control over his or her own data; it also requires access to health insurance in order to procure and use the technology. The DIY artificial pancreas offers patients a more robust of agency but also requires high levels of intellectual capital to hack the devices and make the system work safely. We argue that efforts to increase agency, radically democratize biotechnology, and expand information ownership in the DIY movement are characterized by ideologies and social inequalities that also define corporate pathways.

Urinary metabolites of thromboxane and prostacyclin in diabetes mellitus

1988 ◽  
Vol 118 (2) ◽  
pp. 301-305 ◽  
Author(s):  
K. Gréen ◽  
O. Vesterqvist ◽  
V. Grill
Keyword(s):  
Diabetes Mellitus ◽  
Mass Spectrometry ◽  
Gas Chromatography ◽  
Insulin Treatment ◽  
Artificial Pancreas ◽  
Urinary Metabolites ◽  
Gas Chromatography Mass Spectrometry ◽  
Diabetic State ◽  
In Vivo Synthesis

Abstract. The in vivo synthesis of thromboxane A2 and prostacyclin was estimated in 23 diabetics through measurements of the major urinary metabolites 2,3-dinor-thromboxane B2 and 2,3-dinor-6-keto-PGF1α utilizing gas chromatography-mass spectrometry. Mean excretion was similar to that in non-diabetic subjects. The possible influence of hyperglycemia on the excretion of 2,3-dinor-thromboxane B2 and 2,3-dinor-6-keto-PGF1α was evaluated in three ways: by measuring excretion before and during an acute 9-h normalization of hyperglycemia through an artificial pancreas (Biostator) as well as by comparing excretion before and 7–12 days or 40–180 days after the initiation of insulin treatment. Despite significant reducing effects on hyperglycemia or on levels of hemoglobin A1c, no effects on the excretion of the thromboxane and prostacyclin metabolites could be found. Abnormal formation of thromboxane or prostacyclin is not a generalized feature of the diabetic state.

Alleviating Carbohydrate Counting with a FiASP‐plus‐Pramlintide Closed‐Loop Delivery System (Artificial Pancreas): Feasibility and Pilot Studies

2021 ◽  
Author(s):  
Michael A. Tsoukas ◽  
Elisa Cohen ◽  
Laurent Legault ◽  
Julia E. Oettingen ◽  
Jean‐François Yale ◽  
...  
Keyword(s):  
Delivery System ◽  
Closed Loop ◽  
Artificial Pancreas ◽  
Pilot Studies ◽  
Carbohydrate Counting
Sign in / Sign up

Export Citation Format

Share Document